Note 16 - Collaborative Agreements (Details Textual) - Tuspetinib Licensing Agreement [Member] $ in Millions |
Nov. 04, 2021
USD ($)
shares
|
|---|---|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |
| License Fee, Total | $ 12.5 |
| Payments for License Fee | 5.0 |
| Stock Issued During Period, Value, Licensing Fee | $ 7.5 |
| Stock Issued During Period, Shares, Licensing Fees (in shares) | shares | 7,190 |
| Clinical Development and Global Regulatory Milestone, First Indication | $ 64.5 |
| Clinical Development and Global Regulatory Milestone, Second Indication | 34.0 |
| Clinical Development and Global Regulatory Milestone, Third Indication | 29.0 |
| Global Sales Milestone | $ 280.0 |